杂志简称：korean circ j
中文译名：《韩国循环杂志》
收录属性：scie（2024版）, 目次收录（维普）,英文期刊,
自引率：9.70%
投稿方向：医学、cardiac & cardiovascular systems 心脏和心血管系统
SCI/E期刊基本信息
出版周期：月刊 地区：韩国
中科院分区：4区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：OA期刊
国际标准刊号：ISSN1738-5520；EISSN1738-5555
杂志语言：英语
出版国家：韩国
杂志官网 联系方式
出版地址：101-1704,LOTTE CASTLE PRESIDENT,109,MAPO-DAERO,MAPO-GU,SEOUL,SOUTH KOREA,04146
杂志邮箱：
投稿网址：https://www.editorialmanager.com/kcj
杂志官方网址：https://www.e-kcj.org/
出版商网址：http://www.circulation.or.kr/
杂志投稿要求
投稿须知【杂志社官方网站信息】
Instructions for authors
The Korean Circulation Journal (KCJ) is the official journal of the Korean Society of Cardiology, the Korean Pediatric Heart Society, the Korean Society of Interventional Cardiology, and the Korean Society of Heart Failure. It is an open-access journal publishing monthly in English (https://www.e-kcj.org). It is a professional, international, peer-reviewed journal covering all aspects of cardiovascular medicine, including original researches of preclinical and clinical findings, state of the art reviews, perspectives for outbreaking issues, editorials, images in cardiovascular medicine, and letters to the editor. The journal aims to publish highly qualified and novel researches which improve our understanding of cardiovascular disease, educate students and health professionals, give scientific data to researchers and policy makers, and give benefits in clinical practice to general practitioners.
1. MANUSCRIPT SUBMISSION
The KCJ has an online submission and peer review system and manuscripts must be submitted electronically at https://kcj.edmgr.com. Please first log in as an author and follow the directions. Manuscripts should be submitted by the corresponding author, who must indicate the contact address, phone number, and e-mail for correspondence on the title page of the manuscript. All articles submitted to the Journal must abide by these instructions. Failure to do so will result in return of the manuscript and possible delay in publication. For assistance, please contact us via e-mail, telephone, or fax. Revised manuscripts should be submitted through the same web system under the same manuscript number.
Yangsoo Jang MD, PhD
Editor-in-chief, Korean Circulation Journal
101-1704, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: 82-2-3275-5258, Fax: 82-2-3275-5259
E-mail: herz1@circulation.or.kr
2. EDITORIAL and PEER REVIEW PROCESS
2.1. Peer Review Process
All manuscripts are pre-examined for the format and ethical requirements by managing and ethical consultants, and then decide whether to request external peer review by experts and associate editors in related topics. The authors are blinded when the manuscript is requested for external review. External peer review will be done by at least 2 or more experts in the corresponding field. If needed, editorial staff may request a review from statisticians. The acceptance criteria for all papers are based on the quality and originality of the research and their clinical and scientific contributions in cardiovascular medicine. After request for external review, the initial decision is typically made within 4 weeks with the categories of “accept”, “minor revision”, “major revision”, or “reject”. The results of review and the reviewers’ comments will be sent to the corresponding author via e-mail. After revision according to the comments and recommendations, the corresponding author must submit the revised manuscript in the same E-submission system.
If manuscripts from Editorial Boards of KCJ are submitted, it is also treated through same process with other manuscripts. However, those authors are not involved in the peer reviewer selection, review process, or final decision.
2.2. Revision and Acceptance
When you organize a revised manuscript, you should carefully follow the instructions given in the editor's letter. With each revision, KCJ requires two versions of the manuscript to be resubmitted: one with changes tracked or highlighted and one clean version of the revised manuscript. In your response to the reviewers’ comments, authors have to address each reviewer comment point-by-point and provide the exact page number(s) and line number(s) where each revision was made in the final clean version of the revised manuscript. Failure to do so will cause a delay in the review of your revision. If references, figures or tables are moved, added, or deleted during the revision process, renumber them to reflect the changes so that all references, figures or tables are cited in numeric order.
Failure to resubmit the revised manuscript within 8 weeks without notification to KCJ is considered to be a withdrawal of the manuscript.
2.3. After Decision
Acceptance
The finally accepted manuscript will be reviewed by a manuscript editor for consistency of format and the completeness of references. The manuscript may be revised according to the style guides of the journal. Before publication, the galley proof will be sent via e-mail to the corresponding author for approval.
Complaints or Appeals
Authors, reviewers, readers, and submitters may issue complaints or appeals in cases including follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem.
For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.
The Editor, Editorial Board Members including Ethics Consultant, and Editorial Office is responsible for the handling and resolving the submitted complaints and appeals. A Legal Consultant or Ethics Consultant will be involved with the decision making.
The consequence of resolution will depend on the type or degree of the misconduct and will follow the guidelines of the Committee of Publication Ethics (COPE). If not described above, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals.
3. ETHICS from RESEARCH to PUBLICATION
All manuscripts should be prepared in strict observation of the research and publication ethics guideline recommended by the International Committee of Medical Journal Editors (ICMJE, available at http://www.icmje.org), Council of Science Editors (https://www.councilscienceeditors.org/), World Association of Medical Editors (WAME, http://www.wame.org/), and the Korean Association of Medical Journal Editors (KAMJE, https://www.kamje.or.kr/en/main-en).
All researchers involving animal, cellular, or molecular experiments should record a research note detailing the research process and achievements and follow the research note guidelines of their research institute. If the author’s affiliation is different from the institution that conducts the research, the institution that conducted the research should be marked first, and the original affiliation should be marked separately. KCJ will follow the guideline by the Committee on Publication Ethics (COPE, http://publicationethics.org/) for settlement of any misconduct.
3.1. Statement of Human and Animal Rights
All clinical research must be performed according to the principles embodied in the Declaration of Helsinki: (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects).
Patients have a right to privacy. Therefore, when publishing identifiable images from human research participants, authors must include a statement in the published paper affirming that they have obtained informed consent for publication of the images (unless the consent has waived by an appropriate institutional review board). Images may be cropped to remove nonessential identifying details to protect anonymity but should not be otherwise altered.
Any identifying information, such as patients’ names, initials, hospital numbers, or dates of birth should not be included in images, written descriptions, videos, photographs, and pedigrees unless they are essential for scientific purposes. If identifying characteristics are altered to protect anonymity, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.
Research using animals also should be reviewed by an appropriate committee following the guidelines of the Institutional Animal Care and Use Committee (IACUC). Studies using pathogens requiring a high degree of biosafety should receive permission from a relevant committee such as the Institution Biosafety Committee (IBC).
Authors may be required to provide evidence that they obtained ethical and /or legal approval prior to conducting the research.
3.2. Statement of informed Consents and Institutional Review Board Approval
All researches involving human subjects, human material, or human data must be approved by an appropriate institutional review board.
For all research involving human subjects, informed consent to participate in the study should be obtained from the subjects (or their legally authorized representative), if not waived by the institutional review board.
A statement about this, including the name of the ethics committee and the reference number, must be stated in the methods of manuscript. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption).
In the process of submitting the manuscript, authors will be asked if they have obtained the IRB approval and the reference number need to be provided. The editor of the KCJ may request copies of the informed consent and documents of permission from IRB or related committees.
3.3. Authorship and Contribution
KCJ follows the recommendations for authorship by the ICMJE, 2019 (http://icmje.org/icmje-recommendations.pdf) and Good Publication Practice Guidelines for Medical Journals 3rd Edition (KAMJE, 2019, https://www.kamje.or.kr/board/view?b-name=bo-publication&bo-id=13&per-page=).
Authorship credits should be based on 1) substantial contributions to conception or design, acquisition of data, or analysis and interpretation of the data; AND 2) drafting of the manuscript or revising it critically for important intellectual contents; AND 3) final approval of the version to be published; AND 4) agreement to be accountable for all aspects of the work and ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Authors must meet all of these criteria. In addition, an author should be accountable for the parts of the work he or she has done and should be able to identify which co-authors are responsible for specific other parts of the work. Authors should have confidence in the integrity of the contributions of their co-authors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged as contributors not be authors. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript.
The corresponding author can be only an author(s) who meets all four criteria and cannot be an author who did not meet any one or more of the criteria. The corresponding author should be available throughout the full processes even after publication. When a study is conducted by a large and multicenter group, the group should identify the individual authors who accept responsibility for the manuscript before submission. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as group name. Contributors to the study can be listed in an acknowledgment section. Acquisition of funding, collection of data, or general supervision of the research does not meet the authorship criteria, and such parties should not be listed as authors. If the corresponding author requests the addition or removal of authors after submission, the editor will assess the reason and a written document regarding agreement from all co-authors. The KCJ has no responsibility for changes in authorship.
3.4. Redundant Publication and Plagiarism
Redundant publication is defined as “reporting (publishing or attempting to publish) substantially the same work more than once, without attribution of the original source(s)”. Characteristics of reports that are substantially similar include the following: (a) “at least one of the authors must be common to all reports (if there are no common authors, it is more likely plagiarism than redundant publication),” (b) “the subjects or study populations are the same or overlapped,” (c) “the methodology is typically identical or nearly so,” and (d) “the results and their interpretation generally vary little, if at all.”
When submitting a manuscript, authors should include a letter informing the editor of any potential overlap with other material already published or material being evaluated for publication and should also state how the manuscript submitted to KCJ differs substantially from other materials. If all or part of your patient population was previously reported, this should be mentioned in the Methods, with citation of the appropriate reference(s).
3.4.1 Handling of Misconduct –Corrections & Retractions
KCJ takes all cases of publication misconduct seriously. All reviewers share a responsibility to report any suspected issues with the manuscript to the editor.
If a reviewer or editor raises a concern about suspected cases of research and publication misconduct, such as a redundant publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interests, or an ethical problem, that person should be informed that the Journal editors will perform an investigation. The investigation process will follow the flowchart provided by the Committee on Publication Ethics [COPE] (https://publicationethics.org/resources/flowcharts).
If the investigation confirms any scientific misconduct, a retraction of the article will be published. If warranted, the authors will be invited to prepare the retraction, which should be submitted with an assignment of copyright statement that has been signed by all authors. If the paper has not been published, then the editor can always reject the paper.
Instances of misconduct will be shared with the editorial board of the KCJ. The editor may wish to impose sanctions, notify editors of other biomedical journals, and depending on the severity of the allegation, notify the author’s institution.
KCJ will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when any misconduct is founded.
3.5. Clinical Trials
1) Obligation to register
Clinical trial defined as “any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome” should be registered to the primary registry to be prior publication. KCJ accepts the registration in any of the primary registries that participate in the WHO International Clinical Trials Portal (http://www.who.int/ictrp/en/), NIH ClinicalTrials.gov (http://www.clinicaltrials.gov/), ISRCTN Resister (www.ISRCTN.org), or the Clinical Research Information Service (CRIS), Korea CDC (https://cris.hih.go.kr/cris/index.jsp). The clinical trial registration number shall be published at the end of the abstract.
2) Data sharing statement
KCJ accepts the ICMJE Recommendations for data sharing statement policy (http://icmje.org/icmje-recommendations.pdf). All manuscripts reporting clinical trial results should submit a data sharing statement following the ICMJE guidelines from 1 July 2018.
When the manuscript is submitted, authors should specify the methods of data sharing if it is possible for sharing, otherwise, specify the reason of unable.
Authors may refer to the editorial, “Data Sharing statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors,” in JKMS Vol. 32, No. 7:1051-1053 (http://crossmark.crossref.org/dialog/?doi=10.3346/jkms.2017.32.7.1051&domain=pdf&date-stamp=2017-06-05).
3.6. Conflict of Interest
At manuscript submission, the KCJ requires the corresponding author to summarize all author conflicts of interest disclosures. The conflicts of interest can exist when an author (or author’s institution or employer) has financial or personal relationship or affiliations that could have influence on or bias the authors’ decisions, works, or the manuscript. Such conflicts can be financial support or private connection to pharmaceutical companies, potential pressure from interest groups, or academic benefits.
The KCJ requires complete disclosure of all relevant financial relationships and potential financial conflicts of interest regardless of amount of value. The corresponding author is asked to inform the Editor of all author conflicts of interest that could influence their interpretation of the data.
At manuscript acceptance, the KCJ can ask the authors to confirm and update their disclosure of conflicts of interest online. At the time of publication, the final status of conflicts of interest will be disclosed to the readers on https://www.e-kcj.org. If any author’s disclosure of conflicts of interest is determined to be inaccurate or incomplete after publication, a correction will be published to rectify the original published disclosure statement, and additional action can be taken as necessary.
3.7. Funding
All sources of funding for the study should be listed explicitly and declared under the title of ‘Funding’. The roles of funders were stated in the manuscript including study design, data collection, analysis, any decisions in publication, or preparation of manuscript.
All forms are now signed and submitted electronically. Once the revision manuscript is submitted, the authors will be sent links to complete the electronic Relationship with Industry form and all authors are required to electronically sign a relationship with industry form. Once completed, the further process will be started. Only authors appearing on the final title page will be sent a form.
4. EDITORIAL POLICY
The editorial staffs assume that all authors agreed with the KCJ policies of manuscript submission. Except for the preapproved secondary publication by editor-in-chief, all manuscripts submitted to KCJ must not be previously published in all languages and not be under consideration for submission or publication in other journals. The identities of decision makers will not be disclosed in any circumstances.
5. MANUSCRIPT PREPARATION AND FORMAT
The manuscript should be prepared according to “Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations, formerly the Uniform Requirements for Manuscripts)” (http://www.icmje.org).
All materials must be written in clear, appropriate English using Microsoft Word (doc) or other major word-processing programs.
The manuscript must be double-spaced in 12-point font with 1-inch margin on both sides, top, and bottom on A4 sized paper or North American letter-sized paper.
Author’s summary
The authors of original researches, state of the art reviews, perspectives of the outbreaking issues have to summarize the articles consisting of; what are the unmet needs, important findings for the unmet needs and scientific and clinical meanings of the article. Avoid copying the part of abstract and exceeding 100 words.
Graphic abstract
Select one figure which is representing the finding of the articles of original researches, state of the art reviews, perspectives of the outbreaking issues, images of cardiovascular medicine.
5.1. Original Researches
• Clinical Investigation and Reports: Studies conducted in humans or analysis of human data
• Basic Science Reports: Studies conducted in animals and in vitro experiments
• Word count: ≤ 5000 words excluding the title page, abstract, and tables
• Structured abstract: ≤ 250 words with the following sections: Background and Objectives, Methods, Results, Conclusions. Use complete sentences. All data in the abstract also must appear in the manuscript text or tables
• Keywords: Three to five keywords from the Medical Subject Headings (MeSH) list of Index Medicus
• Number of references: ≤ 30
• Number of figures and tables: ≤ 8
The manuscript should be arranged in the following sequence: 1) Title Page, 2) Abstract, 3) Keywords, 4) Text, 5) Acknowledgements (if applicable), 6) Funding, 7) Disclosures 8) References, 9) Figure Legends, 10) Figures, 11) Tables, and 12) Supplemental Materials. Page numbering should begin with the Title Page.
Title Page
The title page should appear as follows; the title of the manuscript, a short title, names of all authors with their academic degrees and ORCID IDs, total word count of the manuscript, conflict of interests, and funding statement.
– Full title
– Short title (not to exceed 45 characters including spaces)
– Authors’ names including academic degrees and ORCID iDs.
– The contact information for correspondence and reprints, including name, academic degree(s), address (institutional affiliation, city, zip code, and country), telephone and fax numbers, and e-mail address. The corresponding author will be the sole contact for all submission queries.
– Total word count: Include main text, acknowledgement, references, and figure legends. Exclude the title page, abstract, and tables.
– Funding statements: Describe the sources of funding that have supported the work with relevant grant numbers. Please also describe the role of any sponsors or funders and if they had no role, include the following statement at the end of your statement: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”
– Conflict of Interest: Any potential conflicts of interest relevant to the manuscript should be described. If there are no conflicts of interest, authors should state that none exists.